UK COMPETITION AND MARKETS AUTHORITY APPROVES PARAMOUNT SKYDANCE CORPORATION ACQUISITION OF WARNER BROS. DISCOVERY
LOS ANGELES and NEW YORK, Aug. 6, 2026 /PRNewswire/ — The United Kingdom Competition and Markets Authority has today formally cleared the acquisition of Warner... Read more.
Advisors say “show me” as AI and tech giants report earnings
Fidelity Connects Advisor Pulse Polls: Advisors see long-term opportunities in companies using AI to drive growth across sectors TORONTO, Aug. 6, 2026 /CNW/ —... Read more.
ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody... Read more.
Payoneer Reports Second Quarter 2026 Financial Results
10% increase in revenue excluding interest 15% volume growth led by B2B acceleration, up 48% year-over-yearPayoneer announced an agreement to be acquired by Nuvei... Read more.
Nova Reports Record Second Quarter 2026 Financial Results
REHOVOT, Israel, Aug. 6, 2026 /PRNewswire/ — Nova (Nasdaq: NVMI) today announced financial results for the second quarter, the three-month period ended June... Read more.
CME Group Declares Quarterly Dividend
CHICAGO, Aug. 6, 2026 /PRNewswire/ — CME Group Inc., the world’s leading derivatives marketplace, today declared a third-quarter dividend of $1.30 per... Read more.
ATI Announces Second Quarter 2026 Results
ATI Exceeds the High End of Q2 Guidance and Raises Full-Year Outlook GAAP diluted EPS up 56% year-over-yearNet income attributable to ATI increased 50%, adjusted... Read more.
Cars.com Reports Second Quarter 2026 Results
Delivered expected revenue growth and strong profitability, underpinned by focused strategy with highest Marketplace revenue growth in five years Revenue grew to... Read more.
Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Aug. 6, 2026 /PRNewswire/ — Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics, today... Read more.
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI is the most prescribed... Read more.